B. Riley Securities Reiterates Buy on PDS Biotechnology, Raises Price Target to $4
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.
B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.
